Sep 10th 2012 - Edison Investment Research today published a report on ProMetic Life Sciences entitled "Creating Opportunities In H212". In summary, the report says:
ProMetic Life Sciences is confident of continuing a trend of increasing revenues and decreasing EBITDA losses in H212. Improved order visibility suggests FY12 revenues will be at least C$21m, with potential for further upgrades. The company has clearly defined corporate objectives for 2012 and has made solid progress so far. The investment case continues to rest on deriving greater value from its proprietary ligand (binding) enabling technologies as ProMetic moves up the value chain. New contracts (service or product related) could represent upside, as would new agreements for plasma-derived products with strategic partners (such as those recently secured with Hematech and NantPharma) or licensing deals for its novel oral small molecule drugs.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »